PUBLIC COMPANY
save$BBOTBridgeBio Oncology Therapeutics, Inc.
$BBOT3.8900-1.27%South San Francisco, CA, USupdated 21h ago
community read0 votes
🐶 often sniffed alongside
top 1pipeline
2
marketed
0
phase 3
0
catalysts ytd
3
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
2Phase 1
Upcoming
no upcoming catalysts on record
Recent(90d)
view all catalysts →🐶 Hiring Signal
News
- Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra useKaryopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup…biopharma_dive · 22d ago
- BridgeBio Oncology slides as it tightens the scope of its KRAS programBridgeBio Oncology Therapeutics' share price {$BBOT} plummeted by about 24% at market close Wednesday after saying that it plans on scaling back its pipeline to focus on developing its lead KRAS in…endpoints · 23d ago
- A breakthrough pancreatic cancer drug won approval. They still struggle to access itWhen the FDA approved a new pancreatic cancer drug called Rasonque, researchers celebrated. But some patients hoping for quick access have been stymied.stat · 25d ago
Data sources
last refreshed 2m ago
Found something off?
comments(0)
5-min edit window · permanent after that